Improving cancer decisions

Cleveland Diagnostics offers novel, more accurate testing for early detection of cancer and risk of high-grade disease.

Stylized image of blood cells moving through an abstract screen.

Our IsoClear™ Platform

Enabling the rapid development of simpler, clearer cancer diagnostics

Our IsoClear platform measures structural differences in proteins to determine if biomarkers originated in cancer cells. This simple yet robust platform enables the efficient development of a portfolio of affordable blood tests that add clarity to cancer diagnostics.

OUR PLATFORM

Our first test: IsoPSA

Reduces unnecessary prostate biopsies by up to 55%¹

With high sensitivity and a specificity two to three times that of traditional PSA tests, ^2-4 IsoPSA clarifies in whom aggressive cancer may reside—and in whom it may not.

IsoPSA TEST

^{1 Scovell J, et al., Urol. Pract 2022.}
^{2 Klein EA, et al., Eur Urol. 2017.}
^{3 Stovsky M, et al., J Urol. 2019.}
^{4 Podium presentation, AUA-NCS 2021.}